Navigation Links
EntreMed Reports Third Quarter 2008 Financial Results
Date:11/6/2008

tiated in 2006 and 2007. We expect research and development expenses to trend down in the fourth quarter and into 2009 as we collect clinical data and evaluate each program to determine future clinical direction. At the end of the quarter we reported $27.9 million in cash and short-term investments, which together with anticipated royalty inflows, we believe will fund planned operations for at least the next 12 months."

James S. Burns, EntreMed President and Chief Executive Officer, commented, "We are actively pursuing partners for ENMD-2076 and Panzem(R) RA while continuing our clinical oncology programs, including the Phase 1b dose-escalation study in solid tumors for ENMD-2076. The outcome of our partnering initiatives and anticipated clinical progress will guide our priorities through year-end and into 2009. While we are reducing overall expenses, our clinical trials remain on schedule. We anticipate the presentation of clinical and preclinical data for MKC-1, ENMD-2076 and ENMD-1198 over the next several quarters."

Mr. Burns will present a Company overview at the Rodman & Renshaw 10th Annual Healthcare Conference, which will serve as the Company's third quarter 2008 update. Mr. Burns' presentation is scheduled for 2:25 p.m. (ET) on Tuesday, November 11, 2008 and will be web cast. To access the live presentation, visit the Company's web site at http://www.entremed.com. An archive of the presentation will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced canc
'/>"/>

SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. EntreMeds ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model
2. EntreMed to Present at BioPartnering Europe Conference
3. EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market
4. EntreMed Reports Second Quarter 2008 Financial Results
5. EntreMed Appoints Thomas H. Bliss as Senior Vice President of Corporate and Business Development
6. Dana-Farber Cancer Institute Commences Phase 1 Trial With EntreMeds Selective Kinase Inhibitor
7. EntreMed Will Not Seek Shareholder Approval for Reverse Stock Split at Annual Meeting
8. EntreMeds Kinase Inhibitor, ENMD-2076, Presented During AACR Special Session
9. EntreMed Receives Nasdaq Deficiency Notice
10. EntreMed to Present at BioCentury Future Leaders in the Biotech Industry Conference
11. EntreMed Announces 2008 Corporate and Clinical Program Priorities
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Philadelphia’s newest entrepreneurial incubation space is ready for ... The Innovation Center @3401 , a collaborative effort of ... to help attract and nurture start-up businesses in the ... , The Innovation Center @3401 (ic@3401), which is ... the new home of DreamIt Ventures and ...
(Date:7/29/2014)... -- United Therapeutics Corporation (NASDAQ: UTHR ... the second quarter ended June 30, 2014. ... medicines are reaching increasing numbers of patients ... Martine Rothblatt, Ph.D., United Therapeutics, Chairman and ... quarter of our extended-release tablet called Orenitram ...
(Date:7/29/2014)... 2014 Dr. Jason Wendel – recipient of ... one of the Top 10 Plastic Surgeon Specialists for Nashville, ... products. His complete line includes a Hydration Booster, Retexturing Night ... face and skin a younger, more radiant appearance while protecting ... is different, that is why at Dr. J. J. Wendel ...
(Date:7/28/2014)... DIEGO , July 28, 2014 ... cultivation technologies, today announced the appointment of biotechnology veteran ... of the board of directors. Levine replaces Cynthia ,CJ, ... immediately. She will remain chairman of the company,s board ... on Sapphire Energy,s mission to deliver commercial scale algae-based ...
Breaking Biology Technology:Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 2Innovation Center @3401 Opens for Business; DreamIt Ventures and Point.io First Residents 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13Dr. J. J. Wendel Launches New Line of Skin Care Products 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3
... Rice University,s award-winning undergraduate summer research program NanoJapan ... $4 million grant from the National Science Foundation ... from all U.S. universities, combines a traditional study-abroad ... internship in nanotechnology. The program was created in ...
... Sept. 21 Oxford Resource Partners, LP (NYSE: ... today announced their collaborative agreement to develop a pilot ... previously reclaimed from mining operations by Oxford. The goal ... economic viability of biomass production from dedicated energy crops ...
... JERUSALEM, Sept. 21 Chiasma, Inc., a privately ... CEO, will present an overview of the Company at the ... York, New York, on Wednesday, September 22, 2010 at 11:00 ... clinical trial of the investigational new drug Octreolin™, an oral ...
Cached Biology Technology:Rice University's award-winning NanoJapan program wins $4M grant 2Rice University's award-winning NanoJapan program wins $4M grant 3Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio 2Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio 3Oxford Resource Partners, LP and Mendel Biotechnology, Inc. Announce a Miscanthus Biomass Pilot Project in Ohio 4Chiasma to Present at the UBS Global Life Sciences Conference 2Chiasma to Present at the UBS Global Life Sciences Conference 3
(Date:7/29/2014)... bacteria and algae, propel themselves using whip-like appendages ... a millimetre long, function like tiny oars, helping ... cilia are found on the surfaces of many ... liquids over the cell. , Flagella and ... expel pathogens from our airways, they establish the ...
(Date:7/28/2014)... by the U.S. Food and Drug Administration (FDA) for ... bacterial pathogens inside human cells, including those that cause ... published in mBio , the online open-access journal ... way of identifying non-antibiotic drugs that could one day ... drugs on the list inhibit the growth of at ...
(Date:7/28/2014)... reached the South Pole in 1911, but new research ... human. , Using data from 16 ice cores collected ... the South Pole, a group led by Joe McConnell ... created the most accurate and precise reconstruction to date ... record, described in an article published today in the ...
Breaking Biology News(10 mins):Microscopic rowing -- without a cox 2Microscopic rowing -- without a cox 3New route to identify drugs that can fight bacterial infections 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... ranging from the shellfish Swedish people eat at traditional ... their millions in both freshwater and saltwater. One of ... crustacean to have its genome sequenced. A researcher from ... The sequencing has been done in an international ...
... of cancer deaths resulted from metastasis, the spread of ... exploration of the possible mechanical factors that promote metastasis ... is expanding the scientific understanding of what makes malignant ... fibrous matrix that surrounds cancer cells. Karen ...
... SPRING HARBOR, N.Y. (March 22, 2011) - An ... to scientists and nonscientists alike. Its behavior involves processes ... those external to itenvironment and social surroundings. According to ... tapestry of biology: It is sparked when neurons fire ...
Cached Biology News:Surprising results in the first genome sequencing of a crustacean 2WSU proves extracellular matrix tugging creates come hither stimulus for cancer migration 2New book on animal behavior provides integrated view 2
...
Ethylene glycol-bis(2-aminoethyl ether)-N,N,N',N'-tetraacetic acid, Molecular Biology Grade...
... moderate chemiluminescence efficiencies and the chemistry of ... the added benefit that they require simple ... background signal. This benefit has been exploited ... applications. These compounds can also be easily ...
... Deletion Kit for Kilo-Sequencing is designed to ... cloned into the multiple cloning sites (MCS) ... plasmid or phagemid vectors (pUC18/19). The kit ... in the target DNA, thereby progressively moving ...
Biology Products: